JPWO2020005873A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020005873A5 JPWO2020005873A5 JP2020572895A JP2020572895A JPWO2020005873A5 JP WO2020005873 A5 JPWO2020005873 A5 JP WO2020005873A5 JP 2020572895 A JP2020572895 A JP 2020572895A JP 2020572895 A JP2020572895 A JP 2020572895A JP WO2020005873 A5 JPWO2020005873 A5 JP WO2020005873A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridazine
- triazolo
- phenol
- pyrazole
- tetramethylpiperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,2,5,6-tetrahydropyridinyl Chemical group 0.000 claims 278
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 113
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- ZXRCAYWYTOIRQS-UHFFFAOYSA-N hydron;phenol;chloride Chemical compound Cl.OC1=CC=CC=C1 ZXRCAYWYTOIRQS-UHFFFAOYSA-N 0.000 claims 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- JELQZSVKOONUKD-UHFFFAOYSA-N phenol dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC=C1.OC1=CC=CC=C1 JELQZSVKOONUKD-UHFFFAOYSA-N 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 4
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 3
- 125000000033 alkoxyamino group Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 3
- WFJZBOIOPMOUCB-UHFFFAOYSA-N pyridazine;hydrochloride Chemical compound Cl.C1=CC=NN=C1 WFJZBOIOPMOUCB-UHFFFAOYSA-N 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 claims 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- PUBSMDUBHLYMIX-UHFFFAOYSA-N phenol;dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC=C1 PUBSMDUBHLYMIX-UHFFFAOYSA-N 0.000 claims 2
- DNRXKUPYJHTZJE-UHFFFAOYSA-N phenol;hydrobromide Chemical compound Br.OC1=CC=CC=C1 DNRXKUPYJHTZJE-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims 1
- YOUQXTMNMLEWCM-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol Chemical compound OC1=C(C=CC(=C1)C1=CNN=C1)C1=NN=C2N(N=CC2=C1)C1CCNCC1 YOUQXTMNMLEWCM-UHFFFAOYSA-N 0.000 claims 1
- FVXQGVZLCVMFLE-UHFFFAOYSA-N 2-(1-piperidin-4-ylpyrazolo[3,4-c]pyridazin-5-yl)-5-(1H-pyrazol-4-yl)phenol hydrochloride Chemical compound Cl.Oc1cc(ccc1-c1cc2cnn(C3CCNCC3)c2nn1)-c1cn[nH]c1 FVXQGVZLCVMFLE-UHFFFAOYSA-N 0.000 claims 1
- OLYLBVGBSDAEHV-UHFFFAOYSA-N 2-(1H-pyrazol-4-yl)phenol hydrochloride Chemical compound Cl.Oc1ccccc1-c1cn[nH]c1 OLYLBVGBSDAEHV-UHFFFAOYSA-N 0.000 claims 1
- GDUVBKSVYWFWGV-UHFFFAOYSA-N 2-(1h-pyrazol-4-yl)phenol Chemical compound OC1=CC=CC=C1C1=CNN=C1 GDUVBKSVYWFWGV-UHFFFAOYSA-N 0.000 claims 1
- NJYKXOJRBBASGJ-UHFFFAOYSA-N 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-5-(1,2,4-thiadiazol-5-yl)phenol Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=NC=NS1)O)(C)C)C NJYKXOJRBBASGJ-UHFFFAOYSA-N 0.000 claims 1
- QFFQDEGMTBBEMV-UHFFFAOYSA-N 2-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]-1H-benzimidazol-5-ol Chemical compound C1(NC(CC(N2C3=NN=C(C4=C(O)C=C5NC(=NC5=C4)C)C=C3N=N2)C1)(C)C)(C)C QFFQDEGMTBBEMV-UHFFFAOYSA-N 0.000 claims 1
- VTBHBWBXALXSJK-UHFFFAOYSA-N 3-methyl-6-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]benzimidazol-5-ol Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=C(O)C=C3N(C=NC3=C1)C)N=N2)(C)C VTBHBWBXALXSJK-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- YFWCCAXUEVEWBF-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[1-(2,2,6,6-tetramethylpiperidin-4-yl)pyrazolo[3,4-c]pyridazin-5-yl]phenol Chemical compound CC1(NC(CC(C1)N1C2=C(C=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C YFWCCAXUEVEWBF-UHFFFAOYSA-N 0.000 claims 1
- ZEZSKTLJQHOQSU-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[7-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)thieno[3,2-c]pyridazin-3-yl]phenol Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CC(NC(C=1)(C)C)(C)C ZEZSKTLJQHOQSU-UHFFFAOYSA-N 0.000 claims 1
- GIYSUKBTCIPXND-UHFFFAOYSA-N 5-(4-methylpyrazol-1-yl)-2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)triazolo[4,5-c]pyridazin-6-yl]phenol Chemical compound C1(C)(CC(N2C3=C(N=N2)C=C(C2=C(C=C(N4C=C(C=N4)C)C=C2)O)N=N3)CC(C)(C)N1)C GIYSUKBTCIPXND-UHFFFAOYSA-N 0.000 claims 1
- WLVVXZGHMCKLHT-UHFFFAOYSA-N Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound Br.FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WLVVXZGHMCKLHT-UHFFFAOYSA-N 0.000 claims 1
- PXVVRAVHOUCNOQ-UHFFFAOYSA-N BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound BrC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PXVVRAVHOUCNOQ-UHFFFAOYSA-N 0.000 claims 1
- RMBKEKVHYKCBQU-UHFFFAOYSA-N C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(=O)OC1=C(C=CC(=C1)C1=NC=C(C=C1)OC(F)F)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C RMBKEKVHYKCBQU-UHFFFAOYSA-N 0.000 claims 1
- IETUBBFAMCEKDY-UHFFFAOYSA-N C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(C)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C IETUBBFAMCEKDY-UHFFFAOYSA-N 0.000 claims 1
- XXNQVQXOGYTQAO-UHFFFAOYSA-N C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C(CC)N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XXNQVQXOGYTQAO-UHFFFAOYSA-N 0.000 claims 1
- WGGHKOLLPVNZPN-VPYROQPTSA-N C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] Chemical compound C(N1N=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)([2H])([2H])[2H] WGGHKOLLPVNZPN-VPYROQPTSA-N 0.000 claims 1
- AASTXZYIDCCVHJ-UHFFFAOYSA-N C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C Chemical compound C1(C)(CC(N2C3=C(C=C2)N=C(C2=CC(F)=C(C4=CNN=C4)C=C2F)C=N3)CC(C)(C)N1)C AASTXZYIDCCVHJ-UHFFFAOYSA-N 0.000 claims 1
- ZMKXJPXWSNQLIU-UHFFFAOYSA-N C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O Chemical compound C1(CC1)N1C(C=C(C=C1)C1=CC(=C(C=C1)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)O)=O ZMKXJPXWSNQLIU-UHFFFAOYSA-N 0.000 claims 1
- MDLNGIZCASBHMN-UHFFFAOYSA-N C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C Chemical compound C1(NC(CC(C1)N1C2=NN=C(C=C2N=N1)C1=CC=C(C=2C=CNC=2)C=C1O)(C)C)(C)C MDLNGIZCASBHMN-UHFFFAOYSA-N 0.000 claims 1
- HGNVKFMIZLRXNG-UHFFFAOYSA-N C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C Chemical compound C1(NC(CC(C2=CSC3=CC(C4=CC=C(C=5C=NNC=5)C=C4O)=NN=C23)C1)(C)C)(C)C HGNVKFMIZLRXNG-UHFFFAOYSA-N 0.000 claims 1
- DMSDXTCCTHPVTI-UHFFFAOYSA-N C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O Chemical compound C1CN(CCN1)C1=CNC2=C1N=NC(=C2)C1=CC=C(C=2C=NNC=2)C=C1O DMSDXTCCTHPVTI-UHFFFAOYSA-N 0.000 claims 1
- CXMDEHRGUNSXHR-UHFFFAOYSA-N C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound C=1N=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CXMDEHRGUNSXHR-UHFFFAOYSA-N 0.000 claims 1
- IEZREAUMRJSMTC-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CC=NC=C5)O)C.Cl IEZREAUMRJSMTC-UHFFFAOYSA-N 0.000 claims 1
- CJSNRGRIMPZUIK-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CC=C5)O)C.Cl CJSNRGRIMPZUIK-UHFFFAOYSA-N 0.000 claims 1
- AWMVRQRPJPJTOJ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3C=N2)C4=C(C=C(C=C4)C5=CN=CN=C5)O)C.Cl AWMVRQRPJPJTOJ-UHFFFAOYSA-N 0.000 claims 1
- CYRDUAAZDRATQT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN6C=CN=C6N=C5)O)C.Cl CYRDUAAZDRATQT-UHFFFAOYSA-N 0.000 claims 1
- HRJAULMCRJPELB-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=CN=NC=C5)O)C.Cl HRJAULMCRJPELB-UHFFFAOYSA-N 0.000 claims 1
- ARPRJAMVDNNOMT-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NC(=NC=N5)OC)O)C.Cl.Cl ARPRJAMVDNNOMT-UHFFFAOYSA-N 0.000 claims 1
- QXZZNERSSNMHDQ-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=CN=C6C=C5)O)C.Cl QXZZNERSSNMHDQ-UHFFFAOYSA-N 0.000 claims 1
- KYWXKZFVBMQRQY-UHFFFAOYSA-N CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl Chemical compound CC1(CC(CC(N1)(C)C)N2C3=NN=C(C=C3N=N2)C4=C(C=C(C=C4)C5=NN6C=NN=C6C=C5)O)C.Cl KYWXKZFVBMQRQY-UHFFFAOYSA-N 0.000 claims 1
- CSBJUXPHLKVWSL-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(=NC=C1)C(F)(F)F)O)(C)C)C CSBJUXPHLKVWSL-UHFFFAOYSA-N 0.000 claims 1
- LLUUWAIXIGURPB-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=CN=2)O)(C)C)C LLUUWAIXIGURPB-UHFFFAOYSA-N 0.000 claims 1
- QRPNFWFAESPZOV-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=2N(C=C1)N=NC=2)O)(C)C)C QRPNFWFAESPZOV-UHFFFAOYSA-N 0.000 claims 1
- SJJFQXDPRPTDDW-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC=C(C=C1)O)O)(C)C)C SJJFQXDPRPTDDW-UHFFFAOYSA-N 0.000 claims 1
- OVGMNSUGWLZSDU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CN=CS1)O)(C)C)C OVGMNSUGWLZSDU-UHFFFAOYSA-N 0.000 claims 1
- XTEXURNNNAMPIJ-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CSC=C1)O)(C)C)C XTEXURNNNAMPIJ-UHFFFAOYSA-N 0.000 claims 1
- YBSZMQWTRMGMQI-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=CC=2N(N=1)C=NN=2)O)(C)C)C YBSZMQWTRMGMQI-UHFFFAOYSA-N 0.000 claims 1
- DXNAKRLUCGVJEU-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=CN=1)O)(C)C)C DXNAKRLUCGVJEU-UHFFFAOYSA-N 0.000 claims 1
- BSCBHDGQVZTZLE-UHFFFAOYSA-N CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C Chemical compound CC1(NC(CC(C1)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1SC=NN=1)O)(C)C)C BSCBHDGQVZTZLE-UHFFFAOYSA-N 0.000 claims 1
- CDCSEJKBOILEBA-UHFFFAOYSA-N CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=CC=NN1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C CDCSEJKBOILEBA-UHFFFAOYSA-N 0.000 claims 1
- DOHWIWKJZVGRLO-UHFFFAOYSA-N CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl Chemical compound CC1=CN=C(S1)C2=CC(=C(C=C2)C3=NN=C4C(=C3)N=NN4C5CC(NC(C5)(C)C)(C)C)O.Cl DOHWIWKJZVGRLO-UHFFFAOYSA-N 0.000 claims 1
- XJEYOUGWYYHRSH-UHFFFAOYSA-N CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XJEYOUGWYYHRSH-UHFFFAOYSA-N 0.000 claims 1
- PYQQNCSCXQFGMO-UHFFFAOYSA-N CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NN(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PYQQNCSCXQFGMO-UHFFFAOYSA-N 0.000 claims 1
- YLJHBGQTZFIKII-UHFFFAOYSA-N CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C YLJHBGQTZFIKII-UHFFFAOYSA-N 0.000 claims 1
- COKAZEDTDINQIP-UHFFFAOYSA-N CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CC=1OC(=CN=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C COKAZEDTDINQIP-UHFFFAOYSA-N 0.000 claims 1
- XZMKNTZTVAGYFH-UHFFFAOYSA-N CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=CC=C(C=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C XZMKNTZTVAGYFH-UHFFFAOYSA-N 0.000 claims 1
- NXEPJRQTRBYXAO-UHFFFAOYSA-N CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound CN(C1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)C NXEPJRQTRBYXAO-UHFFFAOYSA-N 0.000 claims 1
- QTPNFWZMBNTULA-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QTPNFWZMBNTULA-UHFFFAOYSA-N 0.000 claims 1
- AQEDLCXPALRUPH-UHFFFAOYSA-N CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C AQEDLCXPALRUPH-UHFFFAOYSA-N 0.000 claims 1
- JNKSCAAIDAPBDP-UHFFFAOYSA-N CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CN1N=CC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C JNKSCAAIDAPBDP-UHFFFAOYSA-N 0.000 claims 1
- HAHUVWOHNUHKIM-UHFFFAOYSA-N CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound CNC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HAHUVWOHNUHKIM-UHFFFAOYSA-N 0.000 claims 1
- ZNSFSXYSTJPUPK-UHFFFAOYSA-N COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NC(=NC=N1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C ZNSFSXYSTJPUPK-UHFFFAOYSA-N 0.000 claims 1
- MKKLUEGHXQUPTH-UHFFFAOYSA-N COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound COC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MKKLUEGHXQUPTH-UHFFFAOYSA-N 0.000 claims 1
- OBCDNXOFZPDSIO-GJDMYPNDSA-N C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound C[C@]12CC(C[C@](CC1)(N2)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O OBCDNXOFZPDSIO-GJDMYPNDSA-N 0.000 claims 1
- PWCNKEWBVGFPBI-UHFFFAOYSA-N Cl.Cl.CN1C(CC(CC1(C)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C Chemical compound Cl.Cl.CN1C(CC(CC1(C)C)N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O)(C)C PWCNKEWBVGFPBI-UHFFFAOYSA-N 0.000 claims 1
- WCXRTNTVHFKOKQ-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F Chemical compound FC(OC=1C=CC(=NC=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C)F WCXRTNTVHFKOKQ-UHFFFAOYSA-N 0.000 claims 1
- GDAHALNLMUDALK-UHFFFAOYSA-N FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=CC(=C(C=C1C1=CC=C(C=C1)O)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GDAHALNLMUDALK-UHFFFAOYSA-N 0.000 claims 1
- FIEBCNQTCOVUFG-UHFFFAOYSA-N FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C Chemical compound FC1=NN(C=C1C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C)C FIEBCNQTCOVUFG-UHFFFAOYSA-N 0.000 claims 1
- UECIEINXBYIBJE-UHFFFAOYSA-N FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC1=NNC=C1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UECIEINXBYIBJE-UHFFFAOYSA-N 0.000 claims 1
- GWFQXHPQZZMPQA-UHFFFAOYSA-N FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound FC=1C=NC=CC=1C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C GWFQXHPQZZMPQA-UHFFFAOYSA-N 0.000 claims 1
- HFBKNGRWUHFVPQ-UGKGYDQZSA-N F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C Chemical compound F[C@@H]1C(NC(C[C@@H]1N1N=NC2=C1N=NC(=C2)C1=C(C=C(C=C1)C1=CC(N(C=C1)C)=O)O)(C)C)(C)C HFBKNGRWUHFVPQ-UGKGYDQZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- FSQSBVAAQCSWCM-UHFFFAOYSA-N N1(C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C Chemical compound N1(C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=CC=C(C=3C=NNC=3)C=C1O)N=N2)(C)C)C FSQSBVAAQCSWCM-UHFFFAOYSA-N 0.000 claims 1
- HCJOFNWJQQERIO-UHFFFAOYSA-N N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=C(C=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HCJOFNWJQQERIO-UHFFFAOYSA-N 0.000 claims 1
- FHQBSEMQUDGOFL-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C FHQBSEMQUDGOFL-UHFFFAOYSA-N 0.000 claims 1
- UEDXZYBNXOLLJU-UHFFFAOYSA-N N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC(=CC=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C UEDXZYBNXOLLJU-UHFFFAOYSA-N 0.000 claims 1
- XHXBXPTZXXFGET-UHFFFAOYSA-N N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C XHXBXPTZXXFGET-UHFFFAOYSA-N 0.000 claims 1
- JODJSEHTXZTFLG-UHFFFAOYSA-N N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=CN=CC(=C1)C=1C=CC(=C(C=1)O)C=1C=C2C(=NN=1)N(N=C2)C1CC(NC(C1)(C)C)(C)C JODJSEHTXZTFLG-UHFFFAOYSA-N 0.000 claims 1
- WWUWZMDBLQKHFB-UHFFFAOYSA-N N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1=NC=C(C=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WWUWZMDBLQKHFB-UHFFFAOYSA-N 0.000 claims 1
- UILVXCQQVSAXPF-UHFFFAOYSA-N N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C Chemical compound N1C(CC(CC1(C)C)N1C2=C(N=N1)C=C(C1=NC=C(C=C1O)C=1C=NNC=1)N=N2)(C)C UILVXCQQVSAXPF-UHFFFAOYSA-N 0.000 claims 1
- BMBROBQQCKNBKO-UHFFFAOYSA-N N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N1C=CC=2C1=NC=CC=2C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C BMBROBQQCKNBKO-UHFFFAOYSA-N 0.000 claims 1
- NQBWYLNVMBFSIN-UHFFFAOYSA-N N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O Chemical compound N1CCC(CC1)C1=CNC2=C1N=NC(=C2)C1=C(C=C(C=C1)C=1C=NNC=1)O NQBWYLNVMBFSIN-UHFFFAOYSA-N 0.000 claims 1
- RVAHNMDYQDRSDJ-UHFFFAOYSA-N N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 Chemical compound N1CCC(N2C3=NC=C(N=C3C=N2)C2=CC=C(C=3C=NNC=3)C=C2O)CC1 RVAHNMDYQDRSDJ-UHFFFAOYSA-N 0.000 claims 1
- DHHGMXVHXODILS-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CN2)C=1CC(NC(C=1)(C)C)(C)C DHHGMXVHXODILS-UHFFFAOYSA-N 0.000 claims 1
- XNYIAFCUBYILSN-UHFFFAOYSA-N N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 Chemical compound N1N=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)C(=CS2)C=1CCNCC=1 XNYIAFCUBYILSN-UHFFFAOYSA-N 0.000 claims 1
- QUOQKLKFEJLOTO-UHFFFAOYSA-N N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=C(N2C=1C=NC=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C QUOQKLKFEJLOTO-UHFFFAOYSA-N 0.000 claims 1
- PCHPVTBEHDYBIV-UHFFFAOYSA-N N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=C(C=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C PCHPVTBEHDYBIV-UHFFFAOYSA-N 0.000 claims 1
- HEUANYLFLKGBKC-UHFFFAOYSA-N N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1C=NC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C HEUANYLFLKGBKC-UHFFFAOYSA-N 0.000 claims 1
- MHIYQAQITPPMMQ-UHFFFAOYSA-N N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2C=1N=CC(=C2)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C MHIYQAQITPPMMQ-UHFFFAOYSA-N 0.000 claims 1
- WSLLXTMQGQIZNJ-UHFFFAOYSA-N N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound N=1C=CN2N=C(C=CC2=1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C WSLLXTMQGQIZNJ-UHFFFAOYSA-N 0.000 claims 1
- UESVQKLBZITWBV-UHFFFAOYSA-N NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound NC1=NC=CC(=C1)C=1C=CC(=C(C=1)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C UESVQKLBZITWBV-UHFFFAOYSA-N 0.000 claims 1
- LNAFRHAHLZMSDN-WGOQTCKBSA-N O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C Chemical compound O\N=C\1/CCC2=CC(=C(C=C/12)O)C1=CC2=C(N=N1)N(N=N2)C1CC(NC(C1)(C)C)(C)C LNAFRHAHLZMSDN-WGOQTCKBSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- LRCIGPJGANAIHK-UHFFFAOYSA-N benzene-1,4-diol;dihydrochloride Chemical compound Cl.Cl.OC1=CC=C(O)C=C1 LRCIGPJGANAIHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229960004337 hydroquinone Drugs 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- GEOWCLRLLWTHDN-UHFFFAOYSA-N phenyl formate Chemical compound O=COC1=CC=CC=C1 GEOWCLRLLWTHDN-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- HYHBKLWDTGTBME-UHFFFAOYSA-N pyrazin-1-ium;chloride Chemical compound Cl.C1=CN=CC=N1 HYHBKLWDTGTBME-UHFFFAOYSA-N 0.000 claims 1
- KNPBKKLNMDSNPI-UHFFFAOYSA-N pyridazin-1-ium 2,2,2-trifluoroacetate Chemical compound C1=CN=NC=C1.OC(=O)C(F)(F)F KNPBKKLNMDSNPI-UHFFFAOYSA-N 0.000 claims 1
- BEPZJGUUEAAGDN-UHFFFAOYSA-N pyridin-3-ol dihydrochloride Chemical compound Cl.Cl.Oc1cccnc1 BEPZJGUUEAAGDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690653P | 2018-06-27 | 2018-06-27 | |
| US62/690,653 | 2018-06-27 | ||
| PCT/US2019/038889 WO2020005873A1 (en) | 2018-06-27 | 2019-06-25 | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528467A JP2021528467A (ja) | 2021-10-21 |
| JPWO2020005873A5 true JPWO2020005873A5 (cs) | 2022-06-21 |
| JP7421507B2 JP7421507B2 (ja) | 2024-01-24 |
Family
ID=67180896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572895A Active JP7421507B2 (ja) | 2018-06-27 | 2019-06-25 | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11858941B2 (cs) |
| EP (1) | EP3814357B1 (cs) |
| JP (1) | JP7421507B2 (cs) |
| KR (1) | KR20210042265A (cs) |
| CN (1) | CN112654625A (cs) |
| AR (1) | AR119651A1 (cs) |
| AU (2) | AU2019294478B2 (cs) |
| BR (1) | BR112020026545A2 (cs) |
| CA (1) | CA3103976A1 (cs) |
| CL (3) | CL2020003378A1 (cs) |
| CO (1) | CO2020016285A2 (cs) |
| EA (1) | EA202092896A1 (cs) |
| IL (1) | IL279688A (cs) |
| LT (1) | LT3814357T (cs) |
| MX (1) | MX2020014098A (cs) |
| PE (1) | PE20211378A1 (cs) |
| SG (1) | SG11202012674PA (cs) |
| WO (1) | WO2020005873A1 (cs) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| IL272413B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
| IL275490B2 (en) | 2017-12-22 | 2024-05-01 | Ravenna Pharmaceuticals Inc | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| PE20211378A1 (es) | 2018-06-27 | 2021-07-27 | Ptc Therapeutics Inc | Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR20210135507A (ko) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| JP2022533120A (ja) * | 2019-05-13 | 2022-07-21 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| MX2022005254A (es) | 2019-11-01 | 2022-06-29 | Novartis Ag | El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington. |
| IL298109A (en) | 2020-05-13 | 2023-01-01 | Chdi Foundation Inc | htt modulators for the treatment of Huntington's disease |
| WO2022006550A1 (en) | 2020-07-02 | 2022-01-06 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| TW202216725A (zh) | 2020-07-02 | 2022-05-01 | 美商雷密克斯醫療公司 | 調控剪接之化合物及方法 |
| WO2022060951A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022060944A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| WO2022060943A1 (en) * | 2020-09-16 | 2022-03-24 | Skyhawk Therapeutics, Inc. | Compositions for modulating splicing |
| US20220162610A1 (en) * | 2020-11-12 | 2022-05-26 | Ptc Therapeutics, Inc. | Novel rna transcript |
| US20230405000A1 (en) | 2020-11-13 | 2023-12-21 | Ptc Therapeutics, Inc. | Tablet for use in treating huntington's disease and method of making the same |
| CN116997555A (zh) * | 2021-03-17 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 新颖噻吩并嘧啶酮衍生物 |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| IL310440A (en) | 2021-07-30 | 2024-03-01 | Ptc Therapeutics Inc | Heteroaryl compounds for the treatment of Huntington's disease |
| WO2023081858A1 (en) * | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed-pyrazine amine derivatives for treating sca3 |
| WO2023220134A1 (en) * | 2022-05-10 | 2023-11-16 | Foghorn Therapeutics Inc. | Pyrazine derivatives and uses thereof |
| WO2023244996A2 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
Family Cites Families (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637271A (cs) | 1963-04-04 | 1900-01-01 | ||
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| AU4231293A (en) | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| ES2290951T3 (es) | 1993-05-11 | 2008-02-16 | The University Of North Carolina At Chapel Hill | Oligonucleotidos antisentido que combaten el corte y empalme aberrante y metodos de uso de los mismos. |
| EP0871628A1 (en) | 1995-06-06 | 1998-10-21 | Abbott Laboratories | Quinolizinone type compounds |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| CA2269561C (en) | 1998-04-22 | 2007-06-05 | Dainippon Ink And Chemicals, Inc. | Naphthalene derivative and liquid crystal composition comprising the same |
| EP1115724A1 (en) | 1998-09-21 | 2001-07-18 | Shire Biochem Inc. | Quinolizinones as integrin inhibitors |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| WO2001030757A1 (fr) | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Inhibiteurs de la pompe par liberation de medicaments |
| AU2001230426C1 (en) | 2000-01-24 | 2006-06-22 | Astrazeneca Ab | Therapeutic morpholino-substituted compounds |
| US20050054836A1 (en) | 2000-11-09 | 2005-03-10 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
| WO2002068415A1 (en) | 2000-12-21 | 2002-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| CA2445697A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| MXPA04005510A (es) | 2001-12-07 | 2006-02-24 | Vertex Pharma | Compuestos basados en pirimidina utiles como inhibidores de gsk-3. |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| WO2004019002A2 (en) | 2002-08-23 | 2004-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
| EP1785425B1 (en) | 2002-09-30 | 2009-03-25 | NeuroSearch A/S | 1,4-Diazabicycloalkane derivatives, their preparation and use |
| US20070078144A1 (en) | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
| US7326711B2 (en) | 2003-06-20 | 2008-02-05 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| GB0315494D0 (en) | 2003-07-02 | 2003-08-06 | Biofocus Plc | Compounds which bind to the active site of protein kinase enzymes |
| CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
| CN101723949B (zh) | 2003-12-24 | 2013-10-23 | 生物区科学管理控股有限公司 | 用于治疗呼吸道合胞体病毒感染的多环试剂 |
| SE0400184D0 (sv) | 2004-01-30 | 2004-01-30 | Fyrkloevern Scandinavia Ab | New therapeutical use |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| AU2005232672A1 (en) | 2004-04-08 | 2005-10-27 | Neurogen Corporation | Substituted cinnolin-4-ylamines |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2006219453A (ja) | 2005-02-14 | 2006-08-24 | Tokyo Univ Of Pharmacy & Life Science | キノリン環を母核とする金属識別型二波長性蛍光分子 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| EP1902028A2 (en) | 2005-07-04 | 2008-03-26 | Novo Nordisk A/S | Histamine h3 receptor antagonists |
| US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| US8258109B2 (en) | 2005-10-20 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of LMNA expression |
| WO2007058894A2 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| ATE473978T1 (de) | 2005-12-06 | 2010-07-15 | Neurosearch As | Neue diazabicyclische arylderivate und medizinische verwendung dafür |
| WO2007071055A1 (en) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| WO2007089584A2 (en) | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| EP1999120B1 (en) | 2006-03-28 | 2012-06-27 | High Point Pharmaceuticals, LLC | Benzothiazoles having histamine h3 receptor activity |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| TW200812588A (en) * | 2006-05-15 | 2008-03-16 | Neurogen Corp | CRF1 receptor ligands comprising heteroaryl fused bicycles |
| US7910578B2 (en) | 2006-05-23 | 2011-03-22 | Neurosearch A/S | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use |
| ATE469144T1 (de) | 2006-07-20 | 2010-06-15 | Amgen Inc | Substituierte pyridonverbindungen und anwendungsverfahren |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| DK2066653T3 (da) | 2006-08-03 | 2012-12-10 | Rottapharm Spa | 6-1H-Imidazoquinazolin- og -quinolinderivater, nye stærke analgetika og antiinflammatoriske midler |
| CA2667545A1 (en) | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| AR064517A1 (es) | 2006-12-22 | 2009-04-08 | Avexa Ltd | Pirimidinionas biciclicas y sus usos |
| US20080171792A1 (en) | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
| FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| HUE025976T2 (en) | 2007-09-27 | 2016-05-30 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazolothiadiazoles for use as protein kinase inhibitors |
| WO2009042907A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
| US20090264433A1 (en) | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| CA2728376C (en) | 2008-06-20 | 2015-05-12 | Rottapharm S.P.A. | 6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| WO2010000032A1 (en) | 2008-07-02 | 2010-01-07 | Avexa Limited | Compounds having antiviral properties |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010024903A1 (en) | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| JP2012505898A (ja) | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法 |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| BRPI1008020A2 (pt) | 2009-02-11 | 2016-03-15 | Sunovion Pharmaceuticals Inc | antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos |
| FR2945289A1 (fr) | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| WO2010145208A1 (en) | 2009-06-19 | 2010-12-23 | Abbott Laboratories | Diazahomoadamantane derivatives and methods of use thereof |
| MX340397B (es) | 2009-09-11 | 2016-07-07 | Ionis Pharmaceuticals Inc | Modulacion de expresion de huntingtina. |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| WO2011057204A2 (en) | 2009-11-06 | 2011-05-12 | The Johns Hopkins University | Lrrk2-mediated neuronal toxicity |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| WO2011085990A1 (en) | 2010-01-13 | 2011-07-21 | Institut Pasteur Korea | Anti - infective pyrido (1,2 -a) pyrimidines |
| JP2013518603A (ja) | 2010-02-08 | 2013-05-23 | アイシス ファーマシューティカルズ， インコーポレーテッド | 反復伸張に関連する疾患または病態の治療に有用な方法および組成物 |
| CA2789038A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP3561060A1 (en) | 2010-02-08 | 2019-10-30 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR20180105730A (ko) | 2010-07-19 | 2018-09-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법 |
| WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| CN102617548A (zh) | 2011-01-31 | 2012-08-01 | 北京赛林泰医药技术有限公司 | 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用 |
| WO2012104823A2 (en) | 2011-02-04 | 2012-08-09 | Novartis Ag | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| WO2013019938A1 (en) | 2011-08-02 | 2013-02-07 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
| WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| US20130046093A1 (en) | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
| JP5966014B2 (ja) | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 |
| EA029984B1 (ru) | 2011-12-30 | 2018-06-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| EP2809322B9 (en) | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| HUE039779T2 (hu) | 2012-02-10 | 2019-02-28 | Ptc Therapeutics Inc | Vegyületek gerinc-izomsorvadás kezelésére |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| EP3459942B1 (en) | 2012-04-24 | 2020-12-30 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
| EP2906256B1 (en) | 2012-10-12 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP4144845B1 (en) | 2012-10-12 | 2024-04-24 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| US9227976B2 (en) * | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| WO2014066836A1 (en) | 2012-10-25 | 2014-05-01 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| JP6255711B2 (ja) | 2012-11-01 | 2018-01-10 | 株式会社リコー | エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子 |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| US10260069B2 (en) | 2013-02-04 | 2019-04-16 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| CA2903903C (en) | 2013-03-05 | 2021-05-04 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer |
| JP2016518421A (ja) | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
| CA2913785C (en) | 2013-06-25 | 2021-08-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EA030631B1 (ru) | 2013-07-31 | 2018-09-28 | Новартис Аг | 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| EP3087067B1 (en) * | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| MY193116A (en) | 2014-01-16 | 2022-09-26 | Wave Life Sciences Ltd | Chiral design |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| CA2940621C (en) | 2014-03-14 | 2022-03-15 | Raqualia Pharma Inc. | Azaspiro derivatives as trpm8 antagonists |
| JP2017512834A (ja) | 2014-03-19 | 2017-05-25 | アミディス・ダイアグノスティックス・インコーポレイテッド | アミロイド標的剤及びその使用方法 |
| PL3143025T3 (pl) | 2014-05-15 | 2020-03-31 | F. Hoffmann-La Roche Ag | Związki do leczenia rdzeniowego zaniku mięśni |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| WO2015195811A2 (en) | 2014-06-17 | 2015-12-23 | Novozymes A/S | Biological phosphorus removal from wastewater |
| WO2015197503A1 (en) | 2014-06-25 | 2015-12-30 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
| BR112017011791A2 (pt) | 2014-12-02 | 2018-02-27 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como agentes de controle de pragas |
| RS58862B1 (sr) | 2014-12-24 | 2019-07-31 | Uniqure Ip Bv | Rnki indukovana supresija hantingtonovog gena |
| CA3199430A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| GB201502567D0 (en) | 2015-02-16 | 2015-04-01 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN107635984B (zh) | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| GB201506933D0 (en) | 2015-04-23 | 2015-06-10 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US10226448B2 (en) * | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| MX2018005041A (es) | 2015-11-12 | 2018-08-01 | Hoffmann La Roche | Compuestos para tratar la esclerosis lateral amiotrofica. |
| US10383867B2 (en) | 2015-11-28 | 2019-08-20 | Russell Dahl | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders |
| ES2879995T3 (es) * | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| CN109475531B (zh) * | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
| WO2018022473A1 (en) | 2016-07-25 | 2018-02-01 | Wave Life Sciences Ltd. | Phasing |
| TW201819386A (zh) * | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| WO2018187209A1 (en) | 2017-04-03 | 2018-10-11 | Acceleron Pharma Inc. | Compositions and methods for treating spinal muscular atrophy |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| IL272413B (en) | 2017-08-04 | 2022-09-01 | Skyhawk Therapeutics Inc | Methods and compositions for fusion modulation |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| CA3094690A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2019183364A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| EP3814345A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PE20211378A1 (es) | 2018-06-27 | 2021-07-27 | Ptc Therapeutics Inc | Compuestos heterociclicos y de heteroarilo para tratar la enfermedad de huntington |
| JP2022525417A (ja) | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
| JP2022533120A (ja) | 2019-05-13 | 2022-07-21 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| MX2022005254A (es) | 2019-11-01 | 2022-06-29 | Novartis Ag | El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington. |
| MX2022012575A (es) | 2020-04-09 | 2023-01-24 | Ptc Therapeutics Inc | Compuestos para usarse para tratar la enfermedad de huntington. |
| US20220162610A1 (en) | 2020-11-12 | 2022-05-26 | Ptc Therapeutics, Inc. | Novel rna transcript |
| IL310440A (en) | 2021-07-30 | 2024-03-01 | Ptc Therapeutics Inc | Heteroaryl compounds for the treatment of Huntington's disease |
-
2019
- 2019-06-25 PE PE2020002185A patent/PE20211378A1/es unknown
- 2019-06-25 LT LTEPPCT/US2019/038889T patent/LT3814357T/lt unknown
- 2019-06-25 EA EA202092896A patent/EA202092896A1/ru unknown
- 2019-06-25 MX MX2020014098A patent/MX2020014098A/es unknown
- 2019-06-25 SG SG11202012674PA patent/SG11202012674PA/en unknown
- 2019-06-25 CN CN201980051041.4A patent/CN112654625A/zh active Pending
- 2019-06-25 KR KR1020207036440A patent/KR20210042265A/ko unknown
- 2019-06-25 BR BR112020026545-4A patent/BR112020026545A2/pt unknown
- 2019-06-25 WO PCT/US2019/038889 patent/WO2020005873A1/en unknown
- 2019-06-25 US US17/254,660 patent/US11858941B2/en active Active
- 2019-06-25 JP JP2020572895A patent/JP7421507B2/ja active Active
- 2019-06-25 EP EP19736566.1A patent/EP3814357B1/en active Active
- 2019-06-25 CA CA3103976A patent/CA3103976A1/en active Pending
- 2019-06-25 AU AU2019294478A patent/AU2019294478B2/en active Active
- 2019-06-28 AR ARP190101808A patent/AR119651A1/es unknown
-
2020
- 2020-12-22 IL IL279688A patent/IL279688A/en unknown
- 2020-12-23 CL CL2020003378A patent/CL2020003378A1/es unknown
- 2020-12-24 CO CONC2020/0016285A patent/CO2020016285A2/es unknown
-
2021
- 2021-11-16 CL CL2021003022A patent/CL2021003022A1/es unknown
-
2022
- 2022-12-02 CL CL2022003434A patent/CL2022003434A1/es unknown
-
2023
- 2023-05-23 AU AU2023203241A patent/AU2023203241A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020005873A5 (cs) | ||
| US10934302B1 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| JPWO2019191229A5 (cs) | ||
| JPWO2020005877A5 (cs) | ||
| JP2021503004A5 (cs) | ||
| AU2011240808B2 (en) | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases | |
| AU2021202398A1 (en) | Bicyclic lactams and methods of use thereof | |
| KR20210005558A (ko) | 헌팅턴병 치료 화합물 | |
| DK2773638T3 (en) | HETEROARYLPYRIDON AND AZA PYRIDON COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | |
| JP2017518326A5 (cs) | ||
| JP2020522570A5 (cs) | ||
| JP2014528482A5 (cs) | ||
| US20170145034A1 (en) | Alkynyl alcohols and methods of use | |
| HRP20151232T1 (hr) | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora | |
| JP2018527353A5 (cs) | ||
| CA3085937A1 (en) | Diazaindole compounds | |
| JP2016525092A5 (cs) | ||
| JP2020526549A5 (cs) | ||
| JP2013523884A5 (cs) | ||
| JP2014506929A5 (cs) | ||
| JP2015537010A5 (cs) | ||
| JP2016507551A5 (cs) | ||
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
| JPWO2020231977A5 (cs) | ||
| IL297044A (en) | Compounds for the treatment of Huntington's disease |